research GYNECOMASTIA AFTER FINASTERIDE THERAPY
Finasteride may cause breast enlargement, low testosterone a risk factor.
Search
for
Sort by
Research
150-180 / 1000+ results 
research Prescribing to save patients money: Ethical considerations
Doctors should prescribe cheaper, off-label medication and teach patients how to use it to save money ethically.
research Tamsulosin and Solifenacin : A Dynamic Duo in BPH Management
Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
research Oral administration of berberine represses macrophage activation-associated benign prostatic hyperplasia: a pivotal involvement of the NF-κB
Berberine may reduce prostate enlargement by blocking inflammation.
research Finasteride delays atherosclerosis progression in mice and is associated with a reduction in plasma cholesterol in men
Finasteride may lower cholesterol and slow heart disease progression.
research PD02-05 SRD5A2 EXPRESSION IS A PREDICTOR OF RESPONSE TO FINASTERIDE IN THE MTOPS TRIAL
Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
research MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research Ejaculatory dysfunction in the treatment of lower urinary tract symptoms
Treatments for urinary symptoms often cause ejaculatory problems.
research Novel tip-loaded dissolving and implantable microneedle array patches for sustained release of finasteride
New dissolving and implantable microneedle patches have been created for a long-lasting, non-invasive delivery of the drug finasteride.
research Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia
Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
research 8주 지구성 훈련이 랫 전립선의 자가포식과 전립선비대증에 미치는 영향
Endurance exercise may help BPH by lowering hormones and inflammation.
research One year cross-sectional study of association between androgenetic alopecia and benign prostatic hyperplasia in a tertiary care hospital
There is no link between hair loss and prostate enlargement.
research Lipid Profile and 5α-Reductase Inhibition Activity of Proprietary Ultrahigh-Pressure Supercritical Carbon Dioxide and Hexane Saw Palmetto Extracts
UHP-sCESr is as effective as HESr for treating BPH symptoms.
research Trapa bispinosa Roxb. Pericarp Extract Exerts 5α-Reductase Inhibitory Activity in Castrated Benign Prostatic Hyperplasia Model Mice
Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
research Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.
research 5α-Reductases In Human Physiology: an Unfolding Story
We need to learn more about 5α-reductases and neuroactive steroids to safely make drugs targeting these enzymes.
research Benign prostatic hyperplasia and male lower urinary symptoms: A guide for family physicians
Family doctors can manage older men with urinary symptoms using exams, tests, and medications.
research Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data
Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
research 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
research Editorial: Androgen-dependent diseases and their treatment
Continued research and awareness are needed to improve treatments for androgen-dependent diseases.
research In vitro and In vivo Effects of 17β-N-(4-phenylcarbamoyl) androst-4-en-3- one Derivatives as 5a-reductase Inhibitors on Androgen-dependent Glands
Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
research 5α-Reductases in Human Physiology: An Unfolding Story
Enzymes called 5α-reductases have many body functions and need more research to safely use inhibitors.
research Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
research Synthesis, Characterization and Evaluation of 5α, 6β-Dihalo Androsterone Derivatives as 5α-Reductase Inhibitors
Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
research Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
Taking tadalafil and finasteride together is safe and effective for treating urinary symptoms and erectile dysfunction in men with enlarged prostates.
research Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation
Dihydroartemisinin helps reduce prostate enlargement in rats by stopping the growth of prostate cells.
research High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
Older patients sticking to their prostate medication saw lasting health benefits.
research Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
Polygenic risk scores can predict the risk and outcomes of benign prostatic hyperplasia.
research Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know?
5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.